LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

31.63 1.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.12

Max

32.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+72.84% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	501M 2.1B
Ankstesnė atidarymo kaina	30.25
Ankstesnė uždarymo kaina	31.63

Naujienos nuotaikos

By Acuity

100%

330 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-25 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Infosys Agrees to Acquire Stratus

2026-03-25 23:58; UTC

Uždarbis

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

2026-03-25 23:58; UTC

Uždarbis

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

2026-03-25 23:57; UTC

Uždarbis

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

2026-03-25 23:56; UTC

Uždarbis

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

2026-03-25 23:41; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

2026-03-25 23:41; UTC

Uždarbis

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

2026-03-25 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Declines on Possible Technical Correction -- Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-25 22:08; UTC

Rinkos pokalbiai

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

2026-03-25 22:07; UTC

Uždarbis

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

2026-03-25 21:58; UTC

Rinkos pokalbiai

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

2026-03-25 21:37; UTC

Rinkos pokalbiai

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

2026-03-25 21:14; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

2026-03-25 21:13; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

2026-03-25 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

2026-03-25 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-25 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-03-25 20:33; UTC

Įsigijimai, susijungimai, perėmimai

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

2026-03-25 20:31; UTC

Uždarbis

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

2026-03-25 20:15; UTC

Įsigijimai, susijungimai, perėmimai

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

72.84% į viršų

12 mėnesių prognozė

Vidutinis 53.91 USD 72.84%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.